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plantation, Sanchorawala et al. at Boston University’s
Amyloidosis Center report the use of bortezomib induction
followed by bortezomib-melphalan conditioning in 30 pa-
tients going to stem cell transplantation for immunoglobulin
light chain (AL) amyloidosis [1]. Hematologic responses were
seen in 100% of evaluable patients with an enviable complete
response rate of 63%. This builds on prior work by the same
groupwhere they demonstrated that bortezomib-melphalan
conditioning for AL amyloidosis was both efﬁcacious and
tolerable and did not increase conditioning-related adverse
events [2].
Achieving a complete response in amyloidosis has a
much different impact than it does in multiple myeloma. In
amyloidosis, the toxic immunoglobulin light chain is the
source of the disease, and the clonal population of plasma
cells is relatively small. The ultimate goal of therapy is
organ response and regression of deposits from an
involved organ to restore normal function. As even small
amounts of residual immunoglobulin light chain have the
potential to continue misfolding into an amyloid conﬁgu-
ration, a complete response is necessary for optimal out-
comes [3]. Data from Mayo Clinic on 541 patients analyzed
on an intent-to-treat basis demonstrated the vast differ-
ences in outcome between those who achieved complete
response (42%), those who achieved a partial response
(38%), and those who failed to respond (19%). In fact, when
a complete response is achieved after a stem cell trans-
plantation, in multiple myeloma, the median survival is
59.5 months, whereas it is 113 months for AL patients
achieving a complete response. This prolonged response in
AL amyloidosis likely represents the nonproliferativeFinancial disclosure: See Acknowledgments on page 1340.
* Correspondence and reprint requests: Morie A. Gertz, MD, MACP,
Division of Hematology, Mayo Clinic, 200 First Street, SW, Siebens 670,
Rochester, MN 55905.
E-mail address: gertz.morie@mayo.edu (M.A. Gertz)
1083-8791/ 2015 American Society for Blood and Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2015.04.019biology of amyloid plasma cells leading to slow relapses.
The relative lack of high-risk genetics in AL amyloidosis
that is seen in one quarter of multiple myeloma patients
also favors durable response in AL [4].
At the start of the era of stem cell transplantation for
amyloidosis, it was felt that induction chemotherapy
would not play an important role. This, in large part, is
because at diagnosis, the median percent bone marrow
plasma cells in a patient with AL is 5% to 7%, which would
be considered a very good time point for transplantation
for a patient with multiple myeloma having completed
induction therapy.
Since then, long-term follow-up from the original studies
of bortezomib for relapsed amyloidosis [5] demonstrated a
median overall survival of 62.1 months, a 4-year overall
survival of 75%, and 4 patients receiving prolonged therapy,
indicating the ability of bortezomib to produce durable
responses and longer overall survival. The exciting results
with the use of bortezomib in nontransplantation-eligible
patients with amyloidosis led to combination chemotherapy
trials, including cyclophosphamide-bortezomib-dexametha-
sone, so-called CyBorD, which has been reported to produce a
71% complete response rate and allowed 3 patients, originally
ineligible for transplantation, to go forward with
transplantation, suggesting the potential merit of bortezomib-
based induction before stem cell transplantation [6]. Others
have reported bortezomib induction followed by high-dose
therapy and stem cell reconstitution. Among a group of 31
patients, the overall hematologic response and organ
response rates were 77% and 58%, respectively. The overall
cardiac response rate was 60%, suggesting that bortezomib-
based induction in patients with cardiac involvement be
strongly considered before transplantation [7].
Investigators at Memorial Hospital have explored
consolidation with bortezomib-based therapy after stem
cell transplantation [8]. The therapy plan was to proceed
directly with stem cell transplantation without induction.
For those patients who achieve a complete response,
further chemotherapy exposure could be avoided, but for
those who did not achieve a deep response, consolidation
would be given with bortezomib. At 3 months after
transplantation, 45% had greater than partial response,
including 27% complete responses. Twenty-three patients
R.B. Walter / Biol Blood Marrow Transplant 21 (2015) 1339e13421340received consolidation and 86% had response improvement
within 1 cycle. At 12 months, the complete response rate
was 58% and at 24 months, organ response rates were 70%.
The major barrier to widespread implementation of
stem cell transplantation is the high treatment-related
mortality. In the current article, Sanchorawala et al.
report therapy-related mortality of 8.5%. The group from
Oregon had therapy-related mortality of 9.6% [7], and the
group at Memorial reported 10% treatment-related mor-
tality [8]. These therapy-related mortality rates are
increasingly difﬁcult to justify as new active agents for the
treatment of immunoglobulin light chain amyloidosis
become available. It will be important to properly select
patients at high risk of therapy-related death for exclusion
to achieve the optimal outcomes when combining new
antiplasma cell agents with myeloablative therapy and
stem cell rescue.ACKNOWLEDGMENTS
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Accepted 15 May 2015It is an old platitude that peripheral blood counts are
important in acute myeloid leukemia (AML). Most imme-
diately, they are directly related to the risk of potentially
life-threatening medical events such as bleeding orinfections and, to prevent these events, costly supportive
care needs that are associated with unwanted side effects
and reduced quality of life. For patients who have under-
gone initial chemotherapy and have achieved signiﬁcant
cytoreduction, as indicated by the presence of < 5% blasts
by morphology in the bone marrow and resolution of
extramedullary leukemia, peripheral blood counts also
provide relevant prognostic information. Speciﬁcally,
among such responders, patients who show complete re-
covery of their neutrophil and platelet counts have
repeatedly demonstrated better overall survival, higher
expectation of long-term survival (“cure”), and lower risk
of disease recurrence than those who fail to fully recover
either neutrophils or platelets [1-3]. These differences
support and validate the current recommendations by in-
ternational working groups to separate patients who have
